CSIMarket Company Name, Ticker, Competitors, else..
 
Adverum Biotechnologies Inc   (NASDAQ: ADVM)
 

Adverum Biotechnologies Inc's Suppliers Performance

ADVM's Supply Chain



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
ADVM Costs vs Sales of Suppliers Growth Adverum Biotechnologies Inc's Suppliers recorded an increase in sales by 4.45 % year on year in Q3 2025, sequentially sales grew by 8.26 %, while their net margin rose to 80.68 % year on year, Adverum Biotechnologies Inc's Suppliers improved sequentially profit margin to 8.26 %,

• More on ADVM Suppliers



Adverum Biotechnologies Inc's Suppliers recorded an increase in sales by 4.45 % year on year in Q3 2025, sequentially sales grew by 8.26 %, while their net margin rose to 80.68 % year on year, Adverum Biotechnologies Inc's Suppliers improved sequentially profit margin to 80.68 %,

• More on ADVM Suppliers




Adverum Biotechnologies Inc's Comment on Supply Chain


The company procures raw materials from various suppliers and regularly assesses new raw material suppliers and contract manufacturing organizations (CMOs) to maintain manufacturing flexibility. It has in-house process development capabilities and utilizes global GMP contract manufacturers for clinical and commercial supply. The CMOs have produced multiple batches of Ixo-vec at the proposed commercial scale for clinical trial use.

Adverum Biotechnologies Inc's Comment on Supply Chain


The company procures raw materials from various suppliers and regularly assesses new raw material suppliers and contract manufacturing organizations (CMOs) to maintain manufacturing flexibility. It has in-house process development capabilities and utilizes global GMP contract manufacturers for clinical and commercial supply. The CMOs have produced multiple batches of Ixo-vec at the proposed commercial scale for clinical trial use.


ADVM's Suppliers Net Income grew by ADVM's Suppliers Net margin grew in Q3 to
153.17 % 80.68 %
ADVM's Suppliers Net Income grew by 153.17 %


ADVM's Suppliers Net margin grew in Q3 to 80.68 %


Adverum Biotechnologies Inc's Suppliers Sales Growth in Q3 2025 by Industry

Suppliers from Professional Services Industry      4.45 %
     





ADVM's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Adverum Biotechnologies Inc 102.40 1.60 -204.39 121
Veeva Systems Inc 50,132.76 3,456.71 1,014.77 7,928
Vivosim Labs Inc 0.74 0.11 -12.34 0
Apyx Medical Corp 128.48 58.11 -8.41 205
Bio Green Med Solution Inc 4.81 1.86 -13.23 19
Coherus Oncology inc 119.21 50.94 -132.13 147
SUBTOTAL 1,260,402.45 242,670.23 47,482.69 480,786
24 more Suppliers available

Sign in to see all suppliers for Adverum Biotechnologies Inc .

Sign In Create Free Account


Sources: Adverum Biotechnologies Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Adverum Biotechnologies Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.